Characteristics of the 10 included studies
| Study year . | Study characteristics . | Study population . | MPN . | Follow-up, y . | Antithrombotic treatment . | Reference . |
|---|---|---|---|---|---|---|
| 1991 | Retrospective cohort | N = 103 | ET | Mean 4.8 | Antiplatelet ± cytoreduction (N = 74) | 24 |
| Single center | Age: 9-88 y | Cytoreduction only (N = 15) | ||||
| Italy | ♀/♂: 59/44 | No treatment (N = 14) | ||||
| 2002 | Retrospective cohort | N = 118 | ET | Median 10 | Antiplatelet ± cytoreduction (N = 118) | 25 |
| Single center | Age: mean 62 y | |||||
| Italy | ♀/♂: 69/49 | |||||
| 2008 | Retrospective cohort | N = 494 | ET, PV | Median 5.3 | Antiplatelet ± cytoreduction (N = 351) | 26 |
| Multicenter | Age: median 62 y | VKA ± cytoreduction (N = 79) | ||||
| Italy | ♀/♂: 255/239 | VKA + antiplatelet ± cytoreduction (N = 11) | ||||
| Cytoreduction only (N = 40) | ||||||
| No treatment (N = 13) | ||||||
| 2011 | Retrospective cohort | N = 44 | ET, PV, MF, Unclassified | Median 5.8 | Antiplatelet only (N = 6) | 27 |
| Single center | Age: median 48 y | VKA only (N = 9) | ||||
| Netherlands | ♀/♂: 31/13 | VKA + antiplatelet (N = 6) | ||||
| No treatment (N = 23) | ||||||
| 2016 | Retrospective cohort | N = 181 | ET, PV, PMF | Median 3.2 | Antiplatelet + cytoreduction (N = 6) | 28 |
| Multicenter | Age: median 48 y | Anticoagulation ± cytoreduction (N = 156) | ||||
| Multinational | ♀/♂: 118/63 | Anticoagulation + antiplatelet ± cytoreduction (N = 10) | ||||
| Cytoreduction only (N = 8) | ||||||
| No treatment (N = 1) | ||||||
| 2016 | Retrospective cohort | N = 206 | ET, PV, PMF | Median 2.6 | Antiplatelet ± cytoreduction (N = 11) | 29 |
| Multicenter | Age: median 72 y | Anticoagulation ± cytoreduction (N = 163) | ||||
| Multinational | ♀/♂: 114/92 | Anticoagulation + antiplatelet ± cytoreduction (N = 19) | ||||
| Cytoreduction only (N = 9) | ||||||
| No treatment (N = 5) | ||||||
| 2017 | Prospective cohort | N = 25 | ET, PV | Median 2.1 | DOAC ± cytoreduction (N = 25) | 30 |
| Single center | Age: median 75 y | |||||
| France | ♀/♂: 12/13 | |||||
| 2018 | Case-series | N = 14 | ET, PV, Unclassified | Median 7.4 | VKA ± cytoreduction (N = 9) | 31 |
| Single center | Age: mean 47 y | Antiplatelet ± cytoreduction (N = 2) | ||||
| Northern Ireland | ♀/♂: 11/3 | VKA + antiplatelet ± cytoreduction (N = 3) | ||||
| No treatment (N = 2) | ||||||
| 2019 | Retrospective cohort | N = 78 | ET, PV, MF | Median 5.4 | Anticoagulation ± cytoreduction (N = 71) | 32 |
| Single center | Age: median 53 y | No anticoagulation (N = 7) | ||||
| Germany | ♀/♂: 57 /25 | |||||
| 2020 | Retrospective cohort | N = 32 | ET, PV, MF, Unclassified | Median 2.1 | 33 | |
| Single center | Age: median 50 y | DOAC + cytoreduction (N = 28) | ||||
| United Kingdom | ♀/♂: 18/14 | DOAC + antiplatelet (N = 4) |
| Study year . | Study characteristics . | Study population . | MPN . | Follow-up, y . | Antithrombotic treatment . | Reference . |
|---|---|---|---|---|---|---|
| 1991 | Retrospective cohort | N = 103 | ET | Mean 4.8 | Antiplatelet ± cytoreduction (N = 74) | 24 |
| Single center | Age: 9-88 y | Cytoreduction only (N = 15) | ||||
| Italy | ♀/♂: 59/44 | No treatment (N = 14) | ||||
| 2002 | Retrospective cohort | N = 118 | ET | Median 10 | Antiplatelet ± cytoreduction (N = 118) | 25 |
| Single center | Age: mean 62 y | |||||
| Italy | ♀/♂: 69/49 | |||||
| 2008 | Retrospective cohort | N = 494 | ET, PV | Median 5.3 | Antiplatelet ± cytoreduction (N = 351) | 26 |
| Multicenter | Age: median 62 y | VKA ± cytoreduction (N = 79) | ||||
| Italy | ♀/♂: 255/239 | VKA + antiplatelet ± cytoreduction (N = 11) | ||||
| Cytoreduction only (N = 40) | ||||||
| No treatment (N = 13) | ||||||
| 2011 | Retrospective cohort | N = 44 | ET, PV, MF, Unclassified | Median 5.8 | Antiplatelet only (N = 6) | 27 |
| Single center | Age: median 48 y | VKA only (N = 9) | ||||
| Netherlands | ♀/♂: 31/13 | VKA + antiplatelet (N = 6) | ||||
| No treatment (N = 23) | ||||||
| 2016 | Retrospective cohort | N = 181 | ET, PV, PMF | Median 3.2 | Antiplatelet + cytoreduction (N = 6) | 28 |
| Multicenter | Age: median 48 y | Anticoagulation ± cytoreduction (N = 156) | ||||
| Multinational | ♀/♂: 118/63 | Anticoagulation + antiplatelet ± cytoreduction (N = 10) | ||||
| Cytoreduction only (N = 8) | ||||||
| No treatment (N = 1) | ||||||
| 2016 | Retrospective cohort | N = 206 | ET, PV, PMF | Median 2.6 | Antiplatelet ± cytoreduction (N = 11) | 29 |
| Multicenter | Age: median 72 y | Anticoagulation ± cytoreduction (N = 163) | ||||
| Multinational | ♀/♂: 114/92 | Anticoagulation + antiplatelet ± cytoreduction (N = 19) | ||||
| Cytoreduction only (N = 9) | ||||||
| No treatment (N = 5) | ||||||
| 2017 | Prospective cohort | N = 25 | ET, PV | Median 2.1 | DOAC ± cytoreduction (N = 25) | 30 |
| Single center | Age: median 75 y | |||||
| France | ♀/♂: 12/13 | |||||
| 2018 | Case-series | N = 14 | ET, PV, Unclassified | Median 7.4 | VKA ± cytoreduction (N = 9) | 31 |
| Single center | Age: mean 47 y | Antiplatelet ± cytoreduction (N = 2) | ||||
| Northern Ireland | ♀/♂: 11/3 | VKA + antiplatelet ± cytoreduction (N = 3) | ||||
| No treatment (N = 2) | ||||||
| 2019 | Retrospective cohort | N = 78 | ET, PV, MF | Median 5.4 | Anticoagulation ± cytoreduction (N = 71) | 32 |
| Single center | Age: median 53 y | No anticoagulation (N = 7) | ||||
| Germany | ♀/♂: 57 /25 | |||||
| 2020 | Retrospective cohort | N = 32 | ET, PV, MF, Unclassified | Median 2.1 | 33 | |
| Single center | Age: median 50 y | DOAC + cytoreduction (N = 28) | ||||
| United Kingdom | ♀/♂: 18/14 | DOAC + antiplatelet (N = 4) |
DVT, deep vein thrombosis; PV, polycythemia vera.